TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Anti-HEV IgM presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HEV RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vaccine Initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine Adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) based on clinical toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Hours of CGM data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Wear time of Fitbit activity monitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Medication-assisted treatment (MAT) utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Provider Provision of Buprenorphine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Neuropsychiatric Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participant Health Care Workers With a Positive SARS-CoV2 IgG Antibody Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with an indirect muscle injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: rate of relapse at 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Change in high-density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acceptability of HPV vaccine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Magnitude of Polyethylene Wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NF1 related tumor and non-tumor manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With Clinical Cure at Test of Cure Visit (ITT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Clinical Cure at Test of Cure Visit (CE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in self esteem
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Side Effects (Self-report)
Endpoint domain: Adverse events/effects
Primary endpoint: Blood Markers of Inflammation, Endothelial Injury, and Thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lowest Arterial Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lowest Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of mast cells in COPD lung tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Absence of Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Absence of Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity in diagnosing tumor lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incontinence Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Score Change of The Panic Disorder Severity Scale (PDSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Continuous abstinence from tobacco smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritability frequency and severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hemoglobin A1c Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical Cure at End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve for the Dosing Interval at Steady State (AUCτ,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration at Steady State (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve 0 to Infinity (AUC0-∞) for Warfarin R-enantiomers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration (Cmax) for Warfarin R-enantiomers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve 0 to Infinity (AUC0-∞) for Warfarin S-enantiomers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Social Anxiety Symptoms in Situations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accuracy to localize the cricothyroid membrane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fugl-Meyer assessment of paretic upper limb motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Clear chest CT-scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PCR test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from Baseline Verbal Short-Term Memory (STM) Span
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Urine biomarkers levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Empathic abilities
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ability to retrieve autobiographical memories
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Efficacy of larazotide acetate in treating celiac disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Female Sexual Function Index (FSFI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Normalization of nocturnal blood pressure dipping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety/Toxicity of TD101
Endpoint domain: Adverse events/effects
Primary endpoint: Knee injury and Osteoarthritis Outcome score (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction of Ventricular Therapies (ATP and Shocks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in plasma biomarkers of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fibromyalgia Impact Questionnaire Revised (FIQR) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Levels of circulating and excreted hormones in the pituitary-gonadal axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: anti-pneumococcal immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total Cell Count and Differentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quality of Life: CAT
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life: SGRQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum observed plasma concentration (Cmax) of BMS-986165
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-T) of BMS-986165
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(INF) of BMS-986165
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose-iAUC(0-180min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catheter Related Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Client Satisfaction Scale-3 (CSQ-3)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite of plasma pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of pathogens load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: % of COPD care recommendations received
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Decreased abdominal fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decreased cardio-vascular risks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of opioid analgesics usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CRM Performance During First Sim Scenario (Ottawa Global Rating Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRM Performance During First Sim Scenario (ACLS Checklist)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Reported Pain Intensity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Photoaging scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Psychological Flexibility
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants who report health intervention is useful
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The mean and standard deviation of change in satisfaction with mHealth intervention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Days from Index Screening to Diagnosis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Days from Diagnosis to Treatment Initiation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Patients With an ED Visit/Hospital Readmission Within 30 Days of Craniotomy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: FVC (L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FeNO Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mood assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Understanding of radiation therapy information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Bone Mineral Density (BMD) of the Lumbar Spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Binding of 123I FP-CIT to dopamine transporters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective pain thresholds (thermal pain thresholds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with severe intelligence deficit
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of Grade 3 & 4 neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hematopoiesis enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: HA1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chemotherapy Symptom Assessment Scale (C-SAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Assessment of Cancer Therapy Forum-General - FACT-G (Version 4)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: The self-care agency scale
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Markers of obstruction of blood vessels (vaso-occlusion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Markers of red cell breakdown (hemolysis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Kidney Failure
Endpoint domain: Mortality/survival
Primary endpoint: Change in Thrombogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: IR-MALDESI response to ARVs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident persistent HPV-16 and/or HPV-18 cervical infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 12-Item Motivational Interviewing Coach Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Confirmed Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Anal Sonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoanal manometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nicotine Withdrawal Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modifiers of phenotype in immune system disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality of life assessed using European Organization for Research and Treatment-quality of life questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: RBCs transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: change in migration and wear over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of individuals with pancreatic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: cutaneous adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Identification of metabolites in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of human metabolites in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-Emergent Adverse Event (TEAE) Leading to Discontinuation of Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Pathological remission of cervical intraepithelial neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of ulcer area in the target limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step Length Asymmetric Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step Length Asymmetric Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior capsule flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pectoralis minor resting length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of patients with RNA-HCV undetectable
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: VEGF in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Parent Pain Measure (PPPM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV Antiviral Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of acute exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Invasive Disease-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Child Expressive and Receptive Language Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Social-Emotional Development
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Test- Re-Test reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of modified facilitation technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity POCUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity POCUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: POCUS and radiology/surgery correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in eGFR_CG at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in eGFR_CKD-EPI,cysC at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in eGFR_CKD-EPI,Creatinine at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hospital mortality or discharge to hospice
Endpoint domain: Mortality/survival
Primary endpoint: Target Lesion Percent Stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in maximum blink interval (MBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low Frequency/High Frequency ratio (LF/HF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hemodynamic variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC0-24h) for Tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' score on the Health Education Impact Questionnaire (HEI-Q)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: concentration of exosomes in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in dopamine transporter binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of Severe Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal cachexia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Sedation Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with grade 2 or greater acute mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Low-density Lipoprotein (LDL) Cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of early postoperative delirium
Endpoint domain: Adverse events/effects
Primary endpoint: health effects associated with oil spill clean-up activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness for post-operative treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Expectation for post-operative treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Child behavior during dental treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum markers of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary markers of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and effectiveness of Magnetic Growth Rod
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate hypoparathyroidism (serum calcium <2 mmol/L at day 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Cryoablation Procedure Events (CPEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Significant Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Without Cancer Who Were Recalled
Endpoint domain: Adverse events/effects
Primary endpoint: RT-PCR negative status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in IBD-related symptoms: Pediatric Ulcerative Colitis Activity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in IBD-related symptoms: Pediatric Crohn's Disease Activity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracking adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Concordance Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes